PETACH TIKVA, Israel, March 18, 2013 /PRNewswire/ --
Macrocure (http://www.macrocure.com), a biotechnology company developing advanced cell therapy products, announced today that its poster entitled "A Prospective Multi-Center 24 Week Observational Study Evaluating Wound Healing Outcomes in 131 Patients Treated with Human Activated Leukocytes Suspension, an Advanced Cell Therapy" was accepted for presentation at the upcoming DFCon Conference, set to be held between March 21 - 23 in Los Angeles.
The accepted work summarizes a phase-IV study of adult patients with chronic wounds (diabetic foot ulcers, pressure ulcers, venous ulcers, post-operative ulcers) referred for treatment with CureXcell®. The trial was conducted in seven community wound care clinics in the largest HMO in Israel and enrolled 131 patients. The objective of the study was to determine optimum procedures for use of CureXcell® in the typical Israeli community healthcare setting with a primary endpoint of full wound closure within 24 weeks.
The results of the study showed approximately 70% of the wounds were closed within 24 weeks. Additionally, the conclusion of the study was that CureXCell® appears to be both safe and effective in healing chronic wounds.
"The selection of MacroCure as one of the companies to present at the DFCon Conference is a wonderful opportunity for us to demonstrate our revolutionary technology to the world's leading wound care scientists," said Nissim Mashiach, President & CEO of MacroCure. "We are very proud that our research is advancing the treatment of hard-to-heal wounds and we look forward to continuing to present strong results from the studies and trials we are currently conducting."
MacroCure's poster will be presented by Dr. Latricia Allen, DPM, MPH a physician in the group of Dr. Vickie R. Driver DPM. Dr. Driver is the Podiatric Surgery Division Chief and Research Program Director-Limb Preservation and Wound Healing, Department of Surgery, VA New England Health Care Division. Dr. Driver is also the President Elect of the Association for the Advancement of Wound Care (AAWC).
The poster will be available for viewing throughout the conference.
For more information about the DFCon conference, please visit http://www.dfcon.com.
Macrocure is a biotechnology company which focuses on the development and commercialization of advanced wound care therapies. Macrocure is pursuing regulatory market approval in North America and Europe. CureXcell is also currently undergoing a Phase III randomized, double-blind trial for lower extremity chronic ulcers in adults with diabetes in the United States, Canada and Israel. The product has marketing authorization in Israel for the treatment of chronic ulcers, but is not yet licensed for sale in either the United States or Canada.
Finn Partners Israel for Macrocure